Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_assertion type Assertion NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_head.
- NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_assertion description "[Thus, targeting CD164 may serve as a potential ovarian cancer biomarker, and targeting CD164 may serve as a therapeutic modality in the management of high-grade ovarian tumors.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_provenance.
- NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_assertion evidence source_evidence_literature NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_provenance.
- NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_assertion SIO_000772 24094005 NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_provenance.
- NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_assertion wasDerivedFrom befree-20150227 NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_provenance.
- NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_assertion wasGeneratedBy ECO_0000203 NP804708.RA29EMDHzP9Ypljirz9N2JFrNAR8dJ28cxUKL_Gy1hl4U130_provenance.